ASCENT
Brief summary
ABBV-RGX-314 (also known as RGX-314 and surabgene lomparvovec (sura-vec)) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-vascular endothelial growth factor (VEGF) therapies have significantly changed the landscape for treatment of wet AMD, becoming the standard of care due to their ability to prevent progression of vision loss in the majority of patients. These therapies, however, require life-long intraocular injections, typically repeated every four to 12 weeks in frequency, to maintain efficacy. Due to the burden of treatment, patients often experience a decline in vision with reduced frequency of treatment over time. ABBV-RGX-314 is being developed as a potential one-time treatment for wet AMD.
Interventional study
- 1
- 2
- 3
- 4
Age:
From 50 Years to 89 Years.
Inclusion Criteria:
1. Age ≥ 50 years and ≤ 89 years
2. An ETDRS BCVA letter score between ≤ 78 and ≥ 40 in the study eye
3. Diagnosis of subfoveal choroidal neovascularization (CNV) secondary to AMD in the
study eye previously treated with anti-VEGF
4. Must be pseudophakic (at least 12 weeks postcataract surgery) in the study eye
5. Willing and able to provide written, signed informed consent for this study
6. Participants must have demonstrated a meaningful response to anti-VEGF therapy at
study entry
Inclusion Criteria (Bilateral Treatment Substudy)*:
1. An ETDRS BCVA letter score between ≤ 83 and ≥ 40 in both eyes
2. Diagnosis of subfoveal choroidal neovascularization (CNV) secondary to AMD in both
eyes
3. Must be pseudophakic (at least 12 weeks postcataract surgery) in both eyes
4. Willing and able to provide written, signed informed consent for this study
5. Newcomers must have active disease in the study eye; crossover participants must
have active disease in the eye not treated in the main study
Exclusion Criteria:
1. CNV or macular edema in the study eye secondary to any causes other than AMD
2. Subfoveal fibrosis or atrophy in the study eye
3. Any condition in the investigator's opinion that could limit VA improvement in the
study eye
4. Advanced glaucoma or history of secondary glaucoma in the study eye
5. Myocardial infarction, cerebrovascular accident, or transient ischemic attack within
the past 6 months
6. History of intraocular surgery in the study eye within 12 weeks prior to
randomization
7. History of intravitreal therapy in the study eye, such as intravitreal steroid
injection or investigational medicinal product, other than an intravitreal therapy
for AMD, in the 6 months prior to Week -6
8. Prior treatment with gene therapy
Exclusion Criteria (Bilateral Treatment Substudy)*:
1. CNV or macular edema in either eye secondary to any causes other than AMD
2. Subfoveal fibrosis or atrophy in either eye
3. Any condition in the investigator's opinion that could limit VA improvement in
either eye
4. Advanced glaucoma or history of secondary glaucoma in either eye
5. Myocardial infarction, cerebrovascular accident, or transient ischemic attack within
the past 6 months
6. History of intraocular surgery in either eye within 12 weeks prior to randomization
7. History of intravitreal therapy in the study eye, such as intravitreal steroid
injection or investigational medicinal product, other than an intravitreal therapy
for AMD, in the 6 months prior to Week -6.
8. Prior treatment with gene therapy (*) For previously treated crossover participants,
criteria apply to the eye not treated in the main study only.
Note: Other inclusion/exclusion criteria apply
